No Detail Found!

Beyond Glycemic Control: Exploring the Prospective of Exendin- 4 Clinical Utility as a Disease-Modifying Agent in Alzheimer's Disease; Preclinical and Clinical Evidence

Author(s)
Ahmed El-Sayed Hassan Sulaiman AlRajhi University, College of Medicine, Department of Basic Medical Sciences, AlBukayriyah, Qassim, Saudi Arabia; Zagazig University, College of Medicine, Department of Medical Physiology, Zagazig, Egypt
Eslam Kamal Fahmy Department of Physiology, College of Medicine, Northern Border University (NBU), 91431, Arar, Saudi Arabia; Zagazig University, College of Medicine, Department of Medical Physiology, Zagazig, Egypt
Safya Ebraheem Esmaeel Department of Physiology, College of Medicine, Northern Border University (NBU), 91431, Arar, Saudi Arabia; Zagazig University, College of Medicine, Department of Medical Physiology, Zagazig, Egypt
Alenezi, Mohammad Matar A Department of Physiology, College of Medicine, Northern Border University (NBU), 91431, Arar, Saudi Arabia
Padmanabha B.V. Department of Physiology, College of Medicine, Northern Border University (NBU), 91431, Arar, Saudi Arabia
Saad Elshafey Department of Anatomy, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia
Mohammed M. Ismail Department of Anatomy, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia
Baraah Abu Alsel Medical Sciences and Preparatory Year Department, North Private College of Nursing, Arar, Saudi Arabia
Abstract
Amyloid-beta (Aß) plaques, neurofibrillary tangles of hyperphosphorylated tau, and persistent neuroinflammation are the hallmarks of Alzheimer's disease (AD), a progressive neurodegenerative illness that frequently manifests symptoms of cerebral insulin resistance. The possible neuroprotective properties of Exendin-4 (Ex-4), a long-acting glucagon-like peptide1 receptor agonist (GLP-1RA) currently licensed for type 2 diabetes mellitus (T2DM), have attracted a lot of attention. Ex-4 effectively reduces (Aß) buildup, mitigates tau hyperphosphorylation, and suppresses neuroinflammation and oxidative stress through the GLP-1 receptor (GLP-1R) pathway, as preclinical studies show. Although these data point to Ex-4 as a potentially effective disease-modifying drug, human clinical trials have so far shown conflicting findings about the cognitive and clinical effects of Ex-4 in moderate cognitive impairment (MCI) and early AD. The present body of evidence is summarized in this review, which also examines the known mechanisms of Ex-4 neuroprotection, examines the results of finished clinical studies, and talks about the direction of its clinical use in Alzheimer's disease.
Publication Details
Page(s) 44-47
DOI DOI not available
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: 3, Year: 2026

Request the full text from PASTIC

Keywords
mild cognitive impairment, Neuroprotection, Exendin-4, Clinical trials, Alzheimer's Disease, GLP-1 Receptor Agonist
References
Hoare S.R. “ . .The structure and function of the glucagon-like peptide-1 receptor and its ligands. British Journal of Pharmacology, 146(2005) : 291-301.
Chen C.M. .2017 .Exendin-4 antagonizes the metabolic action of acylated ghrelinergic signaling in the hypothalamic paraventricular nucleus. PLoS One, 12(11) : e0188722.
Eng J. .1992 .Isolation and characterization of exendin-4, a new 39-residue peptide, an agonist for the glucagon-like peptide-1 (GLP-1) receptor, from the venom of the Gila monster (Heloderma suspectum). ” Journal of Biological Chemistry, 267(26) : 18884-18887.
Zhao J.S. .2016 .Truncated glucagon-like peptide-1 and exendin-4 α-conotoxin pl14a peptide chimeras maintain potency and α-helicity and reveal interactions vital for cAMP signaling in vitro. ” Journal of Biological Chemistry, 291(35) : 18321-18332.
Leitgeb Paradiž,E. Paradiž . .Exendin-4 affects calcium signalling predominantly during activation and activity of beta cell networks in acute mouse pancreas tissue slices. ” BMC Biology, 22(2024) : 16.
Shu Z. . .Exendin-4 gene modification and microscaffold encapsulation promote self-persistence and antidiabetic activity of MSCs. Stem Cell Research and Therapy, 15(2024) : 169.
Wang X. . .Exendin-4 antagonizes Aβ1-42 induced attenuation of spatial learning and memory ability. ” Experimental and Therapeutic Medicine, 12(2016) : 2885-2892.
Holscher C. .2022 .The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: an in-depth review. ” Frontiers in Neuroscience, 16 : 970925.
Wang J. . .Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes. ” Journal of Investigative Medicine, 63(2015) : 564-568.
Szafraniec M. . .Beneficial influence of exendin-4 on specific organs and mechanisms favourable for the elderly with concomitant obstructive lung diseases. ” Diseases, 12(2022) : 1090.
Cas Dei,A. Dei . .“Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-ofconcept clinical trial. ” Journal of Endocrinological Investigation, 47(2024) : 629-638.
Zhang Y. .2021 .Association between exenatide use and incidence of Alzheimer's disease.” Alzheimer's and Dementia. , 17(10) : 1601-1609.
0

Citations

0

Downloads

17

Views